Interesting new findings on the differences in nutrient use by our gut bacteria. Are we ready for personalized dietary advice based on microbiome preferences rather than food pyramids?https://t.co/qUH72R0ymM— GutMicrobiota Health (@GMFHx) September 8, 2022
A new study suggests that the natural compound hydroquinine may be effective in fighting multidrug-resistant bacteria, including some that cause hospital infections.
Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SER-109 for the prevention of recurrent C. difficile infection (rCDI).
Join Acurx Pharmaceuticals' Executive Chairman, Robert Deluccia today at 12:00 PM as he discusses the Company's development of Ibezapolstat for the potential treatment of #CDiff. https://t.co/I6ffQbrRiC— Antimicrobials Working Group (@AWG_News) September 7, 2022
.@gianluca1aniro: Alternatives of FMT include defined microbial consortia such as RBX2660 and SER-109 that have shown durable engraftment and good safety profile @esnm_eu #GMFHCoverage pic.twitter.com/I2zOzscgLB— GutMicrobiota Health (@GMFHx) September 6, 2022
Destiny Pharma C. Difficile Treatment Program Gets Positive EU Feedback - MarketWatch
By Joe Hoppe Destiny Pharma PLC said Wednesday that the European Medicines Agency has given positive feedback on its proposed Phase 3 development program for...
$MCRB Seres Therapeutics Announces Completion Of Rolling BLA Submission To FDA For Investigational Microbiome Therapeutic Ser-109 For Recurrent C. Difficile Infection - CML News
Seres Therapeutics Announces Completion of Rolling Bla Submission to FDA for Investigational Microbiome Therapeutic Ser-109 for Recurrent C. Difficile Infection.Seres Therapeutics Inc - Anticipated Product Launch in First Half of 2023.
The FDA's #VRBPAC will meet on September 22 to review data supporting the biologics license application (BLA) for @Rebiotix's RBX2660, a microbiota-based live biotherapeutic studied for its potential to reduce recurrent #CDiff after antibiotic treatment. https://t.co/GClrIVBPna— MTIG (@MTIG_News) August 22, 2022
U of G Vaccine Candidates Listed by World Health Organization - University of Guelph News
Four novel vaccine candidates developed by a University of Guelph chemist have been recently recognized by the World Health Organization (WHO) for potential use in treating what medical experts call a…
FDA Committee Will Meet Next Month for Potential RBX2660 Approval - Contagionlive.com
An FDA advisory committee will meet on September 22, 2022 to decide whether to approve a biologics license application (BLA) for Ferring’s recurrent C difficile biotherapeutic, RBX2660.
SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down
SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, announced that it will be discontinuing its work with the U.S. Department of Defense (DoD) under a prototype research and development agreement. The agreement, which was awarded in the summer of 2019, unde
SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down
SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...
Isobavachalcone From Cullen corylifolium Presents Significant Antibacterial Activity Against Clostridium difficile Through Disruption of the Cell Membrane
Background: Clostridium difficile infection (CDI) has been widely reported in human and animals around the world over the past few decades. The high relapse rate and increasing drug resistance of CDI make the discovery of new agents against C. difficile fairly urgent. This study …
The Effects of Kefir and Kefir Components on Immune and Metabolic Physiology in Pre-Clinical Studies: A Narrative Review - Cureus
Kefir, a fermented beverage made from kefir grains, has gained immense popularity around the world due to its potential health-promoting properties. Kefir beverages are both marketed commerciall...
Scientists engineer probiotic to prevent infection of large intestine - Science Daily
Scientists have created a probiotic to restore bile salt metabolism found in the gastrointestinal tract, to counter the onset and effects of Clostridium Difficile Infection (CDI).
Discovery of a novel natural product inhibitor of Clostridioides difficile with potent activity in vitro and in vivo
Clostridioides difficile infection is a global health threat and remains the primary cause of hospital-acquired infections worldwide. The burgeoning incidence and severity of infections coupled with high rates of recurrence have created an urgent need for novel therapeutics. Here, we report a novel …
Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America - PR Newswire
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
Seres expects to file BLA for C. difficile infection treatment in coming weeks - Seeking Alpha
Seres Therapeutics (MCRB) is trading 16% higher after the company on Wednesday said it expects to complete SER-109, its experimental oral microbiome therapeutic to reduce C
Seres Therapeutics Shares Up 9.8% After Positive Research Results - MarketWatch
By Connor Hart Seres Therapeutics Inc. shares were almost 10% higher Wednesday afternoon after positive research results but below-expected earnings. The...
SER-109: oral microbiome therapy for recurrent Clostridioides difficile infections : SER-109 versus Placebo in the Treatment of Adults with Recurrent Clostridium Difficile Infection (ECOSPOR III)
[SER-109: oral microbiome therapy for recurrent Clostridioides difficile infections : SER-109 versus Placebo in the Treatment of Adults with Recurrent Clostridium Difficile Infection (ECOSPOR III)]
In Vitro Analysis of Extracts of Plant Used in Mexican Traditional Medicine, Which Are Useful to Combat Clostridioides difficile Infection - PubMed
Recently, a worrying acceleration of the emergence of antibiotic-resistant bacteria has been reported. The increase in antibiotic-associated diseases, such as Clostridioides difficile infection (CDI), has promoted research on new treatments that could be more effective and less aggressive for …
